RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Teva Pharmaceutical Industries Stock

Teva Pharmaceutical Industries Equity 2024

Teva Pharmaceutical Industries Equity

7.51 B USD

Ticker

TEVA.TA

ISIN

IL0006290147

WKN

906517

In 2024, Teva Pharmaceutical Industries's equity was 7.51 B USD, a -3.82% increase from the 7.8 B USD equity in the previous year.

Teva Pharmaceutical Industries Aktienanalyse

What does Teva Pharmaceutical Industries do?

Teva Pharmaceutical Industries Ltd is a leading global company in the pharmaceutical industry. The company was founded in 1901 in Jerusalem, Israel, as Salomon, Levin and Company. The name Teva was adopted later in 1976. Teva's business model focuses on manufacturing and distributing high-quality and affordable pharmaceuticals worldwide. The company specializes in generics, as well as specialty pharmaceuticals. Teva has made a name for itself through its strong brand presence, focus on developing affordable medications, and production of biosimilars. Teva is divided into various divisions that focus on the manufacturing and distribution of pharmaceuticals. One of these divisions is the generics division, in which the company targets both the domestic and international markets. Teva's research and development division is known for developing biotechnology-based medications. The specialty pharmaceuticals division focuses on rare and difficult-to-treat diseases, such as multiple sclerosis and Parkinson's disease, and develops new treatment options. Teva is also commercially active in the field of biosimilars, which offer medications based on biological sources. These medications offer higher efficacy and fewer side effects than conventional medications. Teva has taken a leading role in this division by offering medications with high standards, serving a significant growth market. The company offers a variety of products, including prescription medications, over-the-counter products, and veterinary medicine. Some of Teva's popular products include Azilect (a medication for Parkinson's treatment), Copaxone (a medication for multiple sclerosis treatment), QVAR (a medication for asthma treatment), Azor (a medication for hypertension treatment), and ProAir (a medication for asthma treatment). Teva has a long-standing history in the pharmaceutical industry and has established an impressive global presence. The company has strong structures not only in Israel but also in other countries such as the United States, Europe, and Asia. It has maintained an impressive growth strategy and has become a major player in global healthcare. Overall, Teva has established itself as a key company in the pharmaceutical industry. It has a strong focus on affordability and quality of medications, with particular emphasis on the development of biosimilars and biotechnology. The company has a wide range of products and divisions that cater to the needs of customers worldwide. Teva Pharmaceutical Industries ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Teva Pharmaceutical Industries's Equity

Teva Pharmaceutical Industries's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Teva Pharmaceutical Industries's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Teva Pharmaceutical Industries's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Teva Pharmaceutical Industries's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Teva Pharmaceutical Industries’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Teva Pharmaceutical Industries stock

What is the equity of Teva Pharmaceutical Industries this year?

Teva Pharmaceutical Industries has equity of 7.51 B USD this year.

What was the equity of Teva Pharmaceutical Industries compared to the previous year?

The equity of Teva Pharmaceutical Industries has increased/decreased by -3.82% decreased compared to the previous year.

What impact does a high equity have on investors of Teva Pharmaceutical Industries?

A high equity is advantageous for investors of Teva Pharmaceutical Industries as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Teva Pharmaceutical Industries?

A low equity can be a risk for investors of Teva Pharmaceutical Industries, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Teva Pharmaceutical Industries affect the company?

An increase in equity of Teva Pharmaceutical Industries can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Teva Pharmaceutical Industries affect the company?

A reduction in equity of Teva Pharmaceutical Industries can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Teva Pharmaceutical Industries?

Some factors that can affect the equity of Teva Pharmaceutical Industries include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Teva Pharmaceutical Industries so important for investors?

The equity of Teva Pharmaceutical Industries is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Teva Pharmaceutical Industries take to change the equity?

To change equity, Teva Pharmaceutical Industries can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Teva Pharmaceutical Industries pay?

Over the past 12 months, Teva Pharmaceutical Industries paid a dividend of 3.1 USD . This corresponds to a dividend yield of about 0.15 %. For the coming 12 months, Teva Pharmaceutical Industries is expected to pay a dividend of 111.85 USD.

What is the dividend yield of Teva Pharmaceutical Industries?

The current dividend yield of Teva Pharmaceutical Industries is 0.15 %.

When does Teva Pharmaceutical Industries pay dividends?

Teva Pharmaceutical Industries pays a quarterly dividend. This is distributed in the months of April, July, September, December.

How secure is the dividend of Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries paid dividends every year for the past 3 years.

What is the dividend of Teva Pharmaceutical Industries?

For the upcoming 12 months, dividends amounting to 111.85 USD are expected. This corresponds to a dividend yield of 5.33 %.

In which sector is Teva Pharmaceutical Industries located?

Teva Pharmaceutical Industries is assigned to the 'Health' sector.

Wann musste ich die Aktien von Teva Pharmaceutical Industries kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Teva Pharmaceutical Industries from 12/12/2017 amounting to 0.298 USD, you needed to have the stock in your portfolio before the ex-date on 11/28/2017.

When did Teva Pharmaceutical Industries pay the last dividend?

The last dividend was paid out on 12/12/2017.

What was the dividend of Teva Pharmaceutical Industries in the year 2023?

In the year 2023, Teva Pharmaceutical Industries distributed 0 USD as dividends.

In which currency does Teva Pharmaceutical Industries pay out the dividend?

The dividends of Teva Pharmaceutical Industries are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Teva Pharmaceutical Industries

Our stock analysis for Teva Pharmaceutical Industries Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Teva Pharmaceutical Industries Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.